Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Dow
AstraZeneca
Colorcon
Medtronic

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR AXITINIB


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


505(b)(2) Clinical Trials for Axitinib

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT03571438 ↗ Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors Recruiting University Hospital, Grenoble N/A 2017-10-16 The investigators objective is to test the combination directly on organotypic cultures of tumors from patients after their excision in the Department of Urology and Renal Transplantation of the University Hospital of Grenoble and to compare their efficacy with that of currently selected treatments in the clinic. The population targeted by the combination for use in clinical practice is patients with metastatic clear cell renal cell carcinoma. Current treatments for these patients are Sunitinib, Pazopanib and Temsirolimus.
New Combination NCT05070221 ↗ Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis Not yet recruiting Beijing Cancer Hospital Phase 1 2021-10-01 Malignant melanoma, is a kind of malignant tumor derived from melanocytes. It is common in skin, mucous membrane, eye choroid and other parts. Melanoma is one of the fastest growing malignant tumors with an annual incidence rate of 3-5%. In 2012, there were 232000 new cases of melanoma and 55000 deaths worldwide. Though, the incidence rate of melanoma is relatively low in China, it has been increasing rapidly in recent years. Melanoma has seriously endangering the health of Chinese people. Patients with stage Ⅳ melanoma have a poor prognosis. According to statistics, the median survival time of stage M1a melanoma is 15 months, while stage M1b is 8 months. The median survival time of bone metastasis melanoma is 6 months, while liver and brain metastasis is 4 months. The overall median survival time of metastatic melanoma is only 7.5 months, and the 2-year survival rate is 15%. For patients with advanced melanoma, dacarbazine is the only chemotherapy drug approved by NMPA, but its overall effective rate is only 13.4%, and the median survival time is 5.6 ~ 11 months. Therapies(new drugs or new combination treatments)with higher remission rate and longer survival are urgently needed for patients with advanced melanoma.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Axitinib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00071006 ↗ AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS) Completed Pfizer Phase 2 2003-09-01 The study tests the safety and efficacy of axitinib in patients who have the hematologic disease of Acute Myeloid Leukemia or Myelodysplastic Syndrome. The study tests patients who have poor prognosis before entering the study.
NCT00094094 ↗ Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer Completed Pfizer Phase 2 2005-02-01 This is a Phase 2 study being conducted at multiple centers in the United States and Germany. Patients having non-small cell lung cancer that has spread to other parts of the body (i.e., metastatic) or is locally advanced (i.e., Stage IIIB with malignant pleural effusion) are eligible to participate. Patients must have disease that has been treated with at least 1 prior treatment for metastatic disease (prior adjuvant treatment for localized disease does not count as prior treatment for metastatic disease). The purpose of the study is to test whether the angiogenesis inhibitor AG-013736 is an effective treatment for advanced non-small cell lung cancer as shown by the number of patients in the study who experience significant and durable tumor shrinkage
NCT00219557 ↗ AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer Completed Pfizer Phase 2 2005-07-05 This is a Phase 2 study being conducted at multiple centers in the United States, Europe and Canada. Patients having pancreatic cancer that is locally advanced or that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have not had any prior systemic treatment for advanced disease. The purpose of the study is to test whether the angiogenesis inhibitor Axitinib [AG-013736] in combination with gemcitabine is an effective treatment for advanced pancreatic cancer vs. gemcitabine alone by overall survival.
NCT00447005 ↗ Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors Completed Pfizer Phase 1 2007-02-01 To evaluate the clinically recommended dose of AG-013736 (Axitinib) in Japanese patients by reviewing the safety of AG-013736 (Axitinib) following single and multiple dosing.
NCT00471146 ↗ Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer. Completed Pfizer Phase 3 2007-07-01 The purpose of this study is to determine whether investigational study drug, AG-013736, and gemcitabine are effective in the first-line treatment of advanced pancreatic cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Axitinib

Condition Name

Condition Name for Axitinib
Intervention Trials
Renal Cell Carcinoma 13
Clear Cell Renal Cell Carcinoma 10
Metastatic Renal Cell Carcinoma 9
Carcinoma, Renal Cell 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Axitinib
Intervention Trials
Carcinoma, Renal Cell 60
Carcinoma 54
Kidney Neoplasms 11
Neoplasms 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Axitinib

Trials by Country

Trials by Country for Axitinib
Location Trials
United States 490
Japan 66
United Kingdom 38
China 35
Canada 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Axitinib
Location Trials
California 32
Texas 31
New York 26
Ohio 24
Florida 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Axitinib

Clinical Trial Phase

Clinical Trial Phase for Axitinib
Clinical Trial Phase Trials
Phase 3 9
Phase 2/Phase 3 2
Phase 2 92
[disabled in preview] 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Axitinib
Clinical Trial Phase Trials
Completed 59
Recruiting 37
Not yet recruiting 17
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Axitinib

Sponsor Name

Sponsor Name for Axitinib
Sponsor Trials
Pfizer 74
National Cancer Institute (NCI) 13
Merck Sharp & Dohme Corp. 8
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Axitinib
Sponsor Trials
Industry 127
Other 120
NIH 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Harvard Business School
Baxter
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.